Baseline characteristics of patients with isolated PS and controls
| PS, total (n=3910) | Controls, total (n=38 770) | PS, no valve interventions (n=3410) | Controls (n=33 790) | PS, valve interventions (n=500) | Controls (n=4980) | ||
| Female, n (%) | 2139 (54.7) | 21 060 (54.3) | 1901 (55.7) | 18 700 (55.3) | 238 (47.6) | 2360 (47.4) | |
| Median age at registration, years (IQR) | 0.7 (0.3–7.0) | – | 0.8 (0.3–7.7) | – | 0.5 (0.3–3.7) | – | |
| Median follow-up, years (IQR) | 13.5 (6.5–23.5) | 13.8 (6.8–24.5) | 13.5 (6.5–23.5) | 13.8 (6.8–24.5) | 13.9 (6.6–21.5) | 14.5 (6.7–21.5) | |
| Birth period | |||||||
| 1970–1979 | No of patients, n | 246 | 2460 | 215 | 2150 | 31 | 310 |
| Median age at registration, years (IQR) | 12.1 (5.3–28.9) | – | 14.3 (5.3–29.4) | – | 6.6 (4.5–13.3) | – | |
| Median follow-up, years (IQR) | 42.5 (39.6–45.5) | 42.5 (40.5–45.5) | 42.5 (40.5–45.5) | 42.5 (40.5–45.5) | 41.5 (39.5–44.0) | 41.5 (39.5–44.3) | |
| 1980–1989 | No of patients, n | 433 | 4330 | 396 | 3960 | 37 | 370 |
| Median age at registration, years (IQR) | 14.6 (3.1–19.4) | 14.9 (3.6–19.6) | 6.8 (0.9–17.4) | ||||
| Median follow-up, years (IQR) | 31.8 (29.5–34.5) | 31.9 (29.6–34.5) | 31.5 (29.5–34.5) | 31.8 (29.7–34.5) | 34.5 (29.6–35.6) | 34.5 (29.6–35.6) | |
| 1990–1999 | No of patients, n | 786 | 7860 | 659 | 6590 | 127 | 1270 |
| Median age at registration, years (IQR) | 7.1 (1.5–12.1) | 7.8 (2.5–12.4) | 1.7 (0.4–6.8) | ||||
| Median follow-up, years (IQR) | 22.5 (19.8–25.5) | 22.5 (20.5–25.5) | 22.5 (20.5–25.5) | 22.8 (20.5–25.5) | 21.5 (19.6–23.8) | 21.5 (19.7–23.8) | |
| 2000–2009 | No of patients, n | 1294 | 12 770 | 1146 | 11 300 | 148 | 1470 |
| Median age at registration, years (IQR) | 0.6 (0.3–2.6) | – | 0.7 (0.3–2.7) | – | 0.5 (0.3–1.9) | – | |
| Median follow-up, years (IQR) | 12.6 (10.5–15.5) | 12.6 (10.5–15.5) | 12.6 (10.5–15.5) | 12.6 (10.5–15.5) | 12.7 (10.5–15.6) | 12.7 (10.5–15.6) | |
| 2010–2016 | No of patients, n | 1151 | 11 350 | 994 | 9790 | 157 | 1560 |
| Median age at registration, years (IQR) | 0.4 (0.2–0.7) | – | 0.4 (0.3–0.7) | – | 0.3 (0.2–0.5) | – | |
| Median follow-up, years (IQR) | 3.9 (2.5–5.9) | 4.0 (2.6–5.9) | 3.8 (2.5–5.8) | 3.9 (2.5–5.8) | 4.8 (3.5–6.5) | 4.8 (3.5–6.5) | |
| Age of diagnosis | |||||||
| 0–1 year | No of patients, n | 2051 | 20 308 | 1740 | 17 219 | 311 | 3089 |
| Median age at registration, years (IQR) | 0.4 (0.2–0.5) | – | 0.4 (0.2–0.5) | – | 0.3 (0.2–0.5) | – | |
| Median follow-up, years (IQR) | 8.5 (3.7–13.8) | 8.7 (3.9–14.6) | 8.3 (3.6–13.6) | 8.7 (3.8–14.5) | 8.6 (4.8–15.8) | 8.7 (4.8–15.9) | |
| 1–10 years | No of patients, n | 1103 | 10 902 | 962 | 9491 | 141 | 1411 |
| Median age at registration, years (IQR) | 3.8 (2.0–6.7) | – | 3.8 (1.9–6.6) | – | 3.7 (2.0–6.7) | – | |
| Median follow-up, years (IQR) | 16.5 (10.5–22.5) | 16.6 (10.5–22.5) | 15.6 (9.6–22.5) | 16.5 (9.7–22.5) | 20.5 (12.7–26.5) | 20.5 (12.5–26.5) | |
| >10 years | No of patients, n | 756 | 7560 | 708 | 7080 | 48 | 480 |
| Median age at diagnosis, years (IQR) | 16.0 (12.8–21.5) | – | 16.0 (12.8–21.3) | – | 16.1 (12.5–22.3) | – | |
| Median follow-up, years (IQR) | 28.5 (23.5–35.5) | 28.5 (23.5–35.5) | 28.5 (23.5–34.5) | 28.5 (23.5–35.5) | 29.5 (22.3–37.5) | 29.5 (21.5–37.5) | |
PS, pulmonary stenosis.